DK0804239T3 - Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf - Google Patents

Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf

Info

Publication number
DK0804239T3
DK0804239T3 DK94919023T DK94919023T DK0804239T3 DK 0804239 T3 DK0804239 T3 DK 0804239T3 DK 94919023 T DK94919023 T DK 94919023T DK 94919023 T DK94919023 T DK 94919023T DK 0804239 T3 DK0804239 T3 DK 0804239T3
Authority
DK
Denmark
Prior art keywords
stress
drug
enterosoluble
vitamin
manufacturing
Prior art date
Application number
DK94919023T
Other languages
Danish (da)
English (en)
Inventor
Dan Riga
Sorin Riga
Original Assignee
Dan Riga
Sorin Riga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dan Riga, Sorin Riga filed Critical Dan Riga
Application granted granted Critical
Publication of DK0804239T3 publication Critical patent/DK0804239T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94919023T 1994-06-02 1994-06-02 Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf DK0804239T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/RO1994/000003 WO1995033486A1 (en) 1994-06-02 1994-06-02 Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
BR9408581A BR9408581A (pt) 1994-06-02 1994-06-02 Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção

Publications (1)

Publication Number Publication Date
DK0804239T3 true DK0804239T3 (da) 2000-04-03

Family

ID=25664670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94919023T DK0804239T3 (da) 1994-06-02 1994-06-02 Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf

Country Status (11)

Country Link
US (1) US6174890B1 (de)
EP (1) EP0804239B1 (de)
JP (1) JP3455544B2 (de)
AT (1) ATE184490T1 (de)
AU (1) AU694125B2 (de)
BR (1) BR9408581A (de)
CA (1) CA2191837C (de)
DE (1) DE69420746T2 (de)
DK (1) DK0804239T3 (de)
ES (1) ES2139077T3 (de)
WO (1) WO1995033486A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703127A (en) * 1996-01-25 1997-12-30 Pak; Kyoungsik Composition, dosage unit, and method for treating stomach disorders
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
US6337065B1 (en) * 1998-12-01 2002-01-08 University Of Kentucky Research Foundation Method for enhancing protective cellular responses to genotoxic stress in skin
US6726939B1 (en) 2000-03-22 2004-04-27 Kyoungsik Pak Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
EA005383B1 (ru) * 2001-12-28 2005-02-24 Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины" Способ фармакологической коррекции работоспособности человека в экстремальных ситуациях
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
EP1550443A4 (de) * 2002-09-18 2009-04-01 Ajinomoto Kk Zusammensetzung gegen stressbedingte erkrankungen
ITRN20030021A1 (it) * 2003-07-21 2005-01-22 Ascor Chimici Srl Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace.
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
BRPI0511079A (pt) 2004-05-11 2007-12-26 Emotional Brain Bv usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
ITMI20041820A1 (it) * 2004-09-24 2004-12-24 Ascor Chimici Srl Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico.
US20060153900A1 (en) * 2005-01-13 2006-07-13 Pins Joel J Dietary supplement for treatment of lipid risk factors
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US7998500B2 (en) * 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) * 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) * 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
WO2007073006A1 (ja) * 2005-12-22 2007-06-28 Keio University 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
JP2008174512A (ja) * 2007-01-22 2008-07-31 Kracie Seiyaku Kk 起床時疲労感改善用組成物
JP5788715B2 (ja) * 2011-05-31 2015-10-07 キリンホールディングス株式会社 酸素消費量及びエネルギー消費量の低減剤
BR112018071363A2 (pt) 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida
WO2019161331A1 (en) * 2018-02-19 2019-08-22 Marshall Timothy M Magnesium/lithium preparations for neuroprotection and neurotrophic benefits

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493659A (en) 1967-10-23 1970-02-03 Hoffmann La Roche Compositions and process for the production thereof

Also Published As

Publication number Publication date
AU694125B2 (en) 1998-07-16
BR9408581A (pt) 1997-08-26
ATE184490T1 (de) 1999-10-15
JPH10500137A (ja) 1998-01-06
WO1995033486A1 (en) 1995-12-14
AU7010494A (en) 1996-01-04
DE69420746D1 (de) 1999-10-21
EP0804239A1 (de) 1997-11-05
ES2139077T3 (es) 2000-02-01
EP0804239B1 (de) 1999-09-15
DE69420746T2 (de) 2000-06-29
JP3455544B2 (ja) 2003-10-14
US6174890B1 (en) 2001-01-16
CA2191837A1 (en) 1995-12-14
CA2191837C (en) 2002-10-15

Similar Documents

Publication Publication Date Title
DK0804239T3 (da) Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf
US20070098786A1 (en) Enteric valproic acid
ES500186A0 (es) Un metodo, para la preparacion de una formulacion farmaceutica de un agente bioactivo polar.
AU563725B2 (en) Oral controlled release multiple unit formulation
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
ATE334679T1 (de) Feste oral anzuwendende arzneizubereitung mit gesteuerter wirkstoffabgabe enthaltend eine säureempfindliche benzimidazolverbindung
DE3627423A1 (de) Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
IL90435A (en) 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives, their preparation and pharmaceutical compositions containing them
PL323362A1 (en) Method of treating inflammatory inteestine diseases using oral preparations of polyunsaturated omega-3 acids
ATE189771T1 (de) Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält
PT100234A (pt) Novos esteres de alcoois aminados biciclicos e triciclicos, processo para a sua preparacao
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
KR960021060A (ko) 경구 투여용 약제학적 조성물
IT1270239B (it) Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US20100087546A1 (en) Use of dimethyl sulfone (msm) to reduce homocysteine levels
HUP0204513A2 (en) Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
EA199900102A1 (ru) Таблетка малеата тримебутина, покрытая оболочкой
BG103005A (en) Active substance-containing sedimented silicic acids
IT8347760A0 (it) Menti per la loro produzione e premodificazioni cristalline,procediparati farmaceutici che le contengono
ATE329589T1 (de) Multipartikuläre bisoprolol formulierung
CA2411568C (en) Compositions for the therapy of dementias
JPS56110679A (en) 55aminootetrazole derivative of retinoic acid* its manufacture and medicine containing it
EP2654743A1 (de) Kombination aus d-asparaginsäure und l-arginin oder salzen davon zur verbesserung der kognitiven aktivitäten und des gedächtnsses bei demenzen wie seniler demenz und morbus alzheimer
IE802606L (en) Pharmaceutical composition
ATE136783T1 (de) Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung